Feeds:
Posts
Comments

Search Results for 'STATIN'

Original Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in […]

Read Full Post »

Hypertriglyceridemia: Evaluation and Treatment Guideline Reporter and Curator: Dr. Sudipta Saha, Ph.D.   Severe and very severe hypertriglyceridemia increase the risk for pancreatitis, whereas mild or moderate hypertriglyceridemia may be a risk factor for cardiovascular disease. Individuals found to have any elevation of fasting triglycerides should be evaluated for secondary causes of hyperlipidemia including endocrine […]

Read Full Post »

SAR-Cov-2 is probably a vasculotropic RNA virus affecting the blood vessels: Endothelial cell infection and endotheliitis in COVID-19 Reporter: Aviva Lev-Ari, PhD, RN – Bold face and colors are my addition From: “Dr. Larry Bernstein” <larry.bernstein@gmail.com> Reply-To: “Dr. Larry Bernstein” <larry.bernstein@gmail.com> Date: Tuesday, June 2, 2020 at 8:50 AM To: Aviva Lev-Ari <aviva.lev-ari@comcast.net> Subject: Re: […]

Read Full Post »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]

Read Full Post »

Perioperative Statins at Noncardiac Surgery: Survival Up, Complications Down Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 11/26/2018   Clinical Trial: Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) A Cardio-Endo Connection selection by Dharam J. Kumbhani, MD, SM (Trial Summary); Deepak L. Bhatt, MD, MPH (Summary Reviewer) Contribution to Literature: The Statins Evaluation in Coronary […]

Read Full Post »

Live Notes from @HarvardMed Bioethics: Authors Jerome Groopman, MD & Pamela Hartzband, MD, discuss Your Medical Mind Writer: Stephen J. Williams, Ph.D. As part of the Harvard Medical School Series on Bioethics: author, clinician and professor Jerome Groopman, MD and Pamel Harzband, MD gave an online discussion of their book “Your Medical Mind”, a part […]

Read Full Post »

Original Volume One: Perspectives on Nitric Oxide in Disease Mechanisms NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN   Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]

Read Full Post »

@Cleveland Clinic – Serial measurements of high-sensitivity C-reactive protein (hsCRP) post acute coronary syndrome (ACS) may help identify patients at higher risk for morbidity and mortality   Reporter: Aviva Lev-Ari, PhD, RN   Original Investigation March 6, 2019 Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary […]

Read Full Post »

Next »

%d bloggers like this: